Medicare Enrolled

Dr. Brian Dicarlo, MD

Hematology & Oncology · San Luis Obispo, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
892 AEROVISTA PL STE 240, San Luis Obispo, CA 93401
8055418252
In practice since 2007 (19 years)
NPI: 1982728796 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Dicarlo from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Dicarlo? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Dicarlo

Dr. Brian Dicarlo is a hematology & oncology specialist in San Luis Obispo, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Dicarlo performed 250,151 Medicare services across 3,413 unique beneficiaries.

Between the years covered by Open Payments, Dr. Dicarlo received a total of $4,739 from 35 pharmaceutical and/or device companies across 169 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Dicarlo is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 2% volume in CA $4,739 industry payments

Medicare Practice Summary

Medicare Utilization ↗
250,151
Medicare services
Top 2% in CA for hematology & oncology
3,413
Unique beneficiaries
$19
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~13,166 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Pembrolizumab injection (Keytruda) 37,400 $43 $213
Nivolumab injection (Opdivo) 31,384 $24 $120
Daratumumab injection (Darzalex)
An injection containing daratumumab and hyaluronidase-fihj administered under the skin.
30,240 $38 $197
Iron infusion (Feraheme)
An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis.
27,030 $0 $10
Denosumab injection (Prolia/Xgeva) 18,480 $19 $94
Oxaliplatin chemotherapy injection
This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg.
18,400 $0 $54
Darbepoetin injection (Aranesp) for anemia
An injection of darbepoetin alfa used for non-end-stage renal disease purposes.
17,500 $2 $20
Anti-nausea injection (fosaprepitant)
An injection of fosaprepitant, a medication used to prevent nausea and vomiting.
16,650 $0 $10
Paclitaxel chemotherapy injection 16,242 $0 $1
Bevacizumab-bvzr biosimilar injection, 10 mg
An injection of bevacizumab-bvzr, a biosimilar medication, administered in a 10 mg dose.
6,290 $23 $169
Dexamethasone injection (steroid)
An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram.
4,204 $0 $5
Anti-nausea injection (Aloxi/palonosetron) 3,300 $1 $95
Rituximab-pvvr biosimilar injection, 10 mg
An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose.
3,200 $22 $222
Anti-nausea injection (ondansetron/Zofran) 2,632 $0 $11
Injection, leucovorin calcium, per 50 mg 1,900 $3 $20
Intravenous injection of additional new drug or substance
Administration of an additional new medication or substance directly into a vein.
1,500 $13 $245
Normal saline infusion, 250 cc
Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid.
1,155 $1 $10
Pegfilgrastim injection, 0.5 mg
An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions.
1,118 $75 $1,587
Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg 1,040 $11 $445
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
885 $114 $1,071
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
883 $100 $858
Fluorouracil injection, 500 mg
Administration of a 500 mg dose of fluorouracil medication via injection.
870 $2 $17
Complete blood count (CBC) with differential
An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells.
853 $8 $58
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
772 $144 $960
Carboplatin chemotherapy injection, 50 mg
Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection.
739 $2 $259
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg 628 $3 $669
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
607 $12 $120
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
432 $63 $436
Intravenous infusion of new drug or substance, 1 hour or less
This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less.
384 $57 $620
Zoledronic acid injection, 1 mg
An injection of zoledronic acid administered at a dose of 1 mg.
302 $7 $487
Diphenhydramine injection, up to 50 mg
An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams.
301 $1 $10
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
272 $8 $25
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
260 $65 $508
Subcutaneous or intramuscular chemotherapy injection
This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle.
250 $28 $264
Additional sequential IV infusion, 1 hour or less
This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less.
206 $25 $475
Leuprolide acetate (for depot suspension), 7.5 mg 205 $134 $4,038
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
204 $25 $550
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
169 $55 $382
Normal saline infusion, 500 ml
Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution.
146 $1 $15
5% dextrose/water (500 ml = 1 unit) 129 $1 $15
Magnesium sulfate injection, per 500 mg
An injection of magnesium sulfate administered in 500 mg increments.
126 $1 $5
New patient office visit, complex (60-74 min) 115 $177 $1,360
Intravenous push injection of new drug or substance
A healthcare provider injects a new medication or substance directly into a vein using a push technique.
106 $49 $447
Prolonged intravenous chemotherapy administration
This procedure involves the administration of chemotherapy medication directly into a vein over an extended period.
101 $114 $1,196
Normal saline infusion, 1000 cc
Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution.
100 $2 $25
Additional hour of intravenous infusion
This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis.
97 $18 $150
Irrigation of implanted venous access device
This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids.
80 $22 $183
Additional hour of intravenous hydration
This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy.
72 $11 $225
Concurrent intravenous infusion
Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given.
49 $17 $103
Vitamin B-12 injection
An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg.
39 $1 $13
Intravenous hydration infusion, 31-60 minutes
Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes.
32 $29 $315
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
24 $122 $1,085
Intravenous drug injection
A procedure involving the administration of a medication or substance directly into a vein.
22 $33 $388
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
15 $98 $680
Office visit, established patient (10-19 min)
An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition.
11 $44 $354
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
12.1% high complexity
86.4% medium
1.5% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$4,739
Total received (2018-2024)
Avg $677/year across 7 years
Top 44% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
35
Companies
169
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,250 (68.6%)
Other
Charitable contributions, space rental, and other categories
$1,098 (23.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$392 (8.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$421
2023
$625
2022
$638
2021
$939
2020
$18
2019
$393
2018
$1,706

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Genmab U.S., Inc.
$125
ABBVIE INC.
$112
PFIZER INC.
$54
Abbott Laboratories
$46
Merck Sharp & Dohme LLC
$37
E.R. Squibb & Sons, L.L.C.
$25
Medtronic, Inc.
$22
Top 3 companies account for 69.1% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,258
E.R. Squibb & Sons, L.L.C.
$549
Lilly USA, LLC
$249
AstraZeneca Pharmaceuticals LP
$247
Pharmacyclics LLC, An AbbVie Company
$242
Genentech USA, Inc.
$211
Amgen Inc.
$192
NOVARTIS PHARMACEUTICALS CORPORATION
$167
Janssen Biotech, Inc.
$159
Merck Sharp & Dohme LLC
$131
Pharmacyclics LLC, an AbbVie Company
$131
ABBVIE INC.
$125
Genmab U.S., Inc.
$125
PFIZER INC.
$108
Takeda Pharmaceuticals U.S.A., Inc.
$102
Clovis Oncology, Inc.
$88
Exelixis Inc.
$88
Daiichi Sankyo Inc.
$71
Secura Bio, Inc.
$50
Celgene Corporation
$48
Abbott Laboratories
$46
Medtronic, Inc.
$43
TOLMAR Pharmaceuticals, Inc.
$42
Array BioPharma Inc.
$35
EMD Serono, Inc.
$33
Merck Sharp & Dohme Corporation
$31
SANOFI-AVENTIS U.S. LLC
$29
GENZYME CORPORATION
$22
Dendreon Pharmaceuticals LLC
$21
Regeneron Healthcare Solutions, Inc.
$18
Seattle Genetics, Inc.
$18
Ipsen Biopharmaceuticals, Inc
$16
Gilead Sciences, Inc.
$15
TESARO, Inc.
$14
Puma Biotechnology, Inc.
$14
Top 3 companies account for 43.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · Aranesp · BOSULIF · Braftovi · CAMZYOS · CREON · Cabometyx · DARZALEX · ELIGARD · ELREXFIO · EMEND · EMPLICITI · EPKINLY · Epkinly · Erivedge · Erleada · FARYDAK · FASLODEX · FREESTYLE LIBRE 3 · GAZYVA · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INTELLIS ADAPTIVESTIM · Imbruvica · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LORBRENA · LYNPARZA · MEKINIST · NINLARO · Nerlynx · Neulasta · Nplate · OPDIVO · Onivyde · PROMACTA · PROVENGE · Perjeta · Rubraca · SANDOSTATIN LAR · SYNCHROMEDII · TAGRISSO · TASIGNA · TECENTRIQ · TEPMETKO · VENCLEXTA · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (69%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a hematology & oncology specialist in San Luis Obispo?
Compare hematology & oncology specialists in the San Luis Obispo area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
9
Per 100K population
3.2
County median income
$93,398
Nearest hospital
FRENCH HOSPITAL MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Dicarlo is a mixed practice specialist, with above-average Medicare volume (top 2% in CA), with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Dicarlo experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Dicarlo performed 37,400 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Dicarlo receive payments from pharmaceutical companies?
Yes. Dr. Dicarlo received a total of $4,739 from 35 companies across 169 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Dicarlo's costs compare to other hematology & oncology specialists in San Luis Obispo?
Dr. Dicarlo's average Medicare payment per service is $19. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Dicarlo) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →